The present invention is a general formula (I) wherein A is phenyl or a 6-membered heteroaryl group selected from (II) containing 1 or 2 N atoms； R 1 is S (O) 2 lower alkyl, S (O) 2 NR 4 R 5 , S (O) 2 cycloalkyl, S-lower alkyl, or S (O) 2 -azetidin-1-yl； R 4 and R 5 , independently of one another, are hydrogen, lower alkyl, or (CH 2 ) 2 OCH 3 ； or alternatively, the group A—R 1 together with two adjacent carbon atoms from the group A Further fused rings selected from (III) may be formed； R 2 is hydrogen or cycloalkyl； R 3 is methyl or halogen； n is 1 or 2； X Is N, N + O − , or CH； Or, -CH 2 - indolin-2-one derivative represented by there can), the well, its pharmaceutically acceptable salts, racemic mixtures, or the corresponding enantiomers and / or optical isomers thereof and / or Relates to stereoisomers. The compound is a CNS disease, substance abuse, alcohol and drug addiction, obsessive-compulsive disorder, cognitive impairment, bipolar disorder, mood disorder, major depression, treatment resistance associated with positive (psychiatric) and negative symptoms of schizophrenia Depression, anxiety disorder, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disorder, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, Huntington's disease, ADHD, muscle atrophy It can be used for the treatment of lateral sclerosis, arthritis effects, autoimmune diseases, viral and fungal infections, cardiovascular diseases, ophthalmic and inflammatory retinal diseases, and neurodevelopmental disorders involving balance disorders, epilepsy and epilepsy.本発明は、一般式（Ｉ）（式中、Ａは、フェニルであるか、又は、１個もしくは２個のＮ原子を含有する、（ＩＩ）から選択される６員ヘテロアリール基であり；Ｒ１は、Ｓ（Ｏ）２低級アルキル、Ｓ（Ｏ）２ＮＲ４Ｒ５、Ｓ（Ｏ）２シクロアルキル、Ｓ－低級アルキル、又はＳ（Ｏ）２－アゼチジン－１－イルであり；Ｒ４及びＲ５は、互いに独立して、水素、低級アルキル、又は（ＣＨ２）２ＯＣＨ３であるか；あるいは、基Ａ－Ｒ１は、基Ａからの隣接する２つの炭素原子と共に、（ＩＩＩ）から選択される、更なる縮合環を形成してもよく；Ｒ２は、水素又はシクロアルキルであり；Ｒ３は、メチル又はハロゲンであり；ｎは、１又は２であり；Ｘは、Ｎ、Ｎ＋Ｏ－、又はＣＨであり；破線－－－は、存在しないか、又は、－ＣＨ２－でありうる）で示
